Bizengri Approved to Treat Some Lung, Pancreatic Cancers
Mar 26, 2025 · FDA has approved zenocutuzumab (Bizengri) to treat lung and pancreatic cancers with a rare genetic alteration called an NRG1 fusion.
Accelerated approval for drug targeting NRG1 - Lung Cancer …
Jan 14, 2025 · The good news The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco for the treatment of adult patients with …
FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
Zenocutuzumab: Uses in Cancer, Side Effects, Dosages, …
Mar 3, 2025 · What Cancers Is Zenocutuzumab Approved to Treat? Zenocutuzumab has received FDA approval for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) …
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective …
A patient with CD74–NRG1 -positive non–small cell lung cancer who had progressed on six prior lines of systemic therapy, including afatinib, responded rapidly to treatment with a partial …
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers …
Feb 6, 2025 · The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an …
What the FDA Approval of Bizengri Means for Patients With NRG1 …
Mar 6, 2025 · The Food and Drug Administration (FDA) has granted its first approval for a systemic therapy for patients with non-small cell lung cancer (NSCLC) with an Neuregulin 1 …
FDA Approves Zenocutuzumab-zbco to Treat Non-small Cell Lung Cancer …
Feb 20, 2025 · On 4 December 2024, FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri®) for the treatment of adults with advanced, unresectable, or metastatic non-small …
First Systemic Therapy Approved for Lung and Pancreatic Cancers …
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated …
Trial Supports Bizengri as a Promising Treatment for NRG1 Fusion ...
Apr 3, 2025 · Infusion-related reactions were noted in 14% of patients, and only one patient discontinued the treatment due to a treatment-related adverse event. “Based on the …